Targeting CDK7/9 and casein kinase 1 alpha as a therapeutic strategy in advanced-stage uveal melanoma
Uveal melanoma (UM) patients frequently develop advanced-stage disease in the liver, but treatment options are limited. The low tumor mutation burden and the transcriptional rewiring observed in aggressive, BRCA1-associated protein 1 (BAP1)-deficient UM led us to investigate transcriptional-based inhibitors in preclinical models. Drug screening data and analysis of the Dependency Map (DepMap) indicated that UM cell lines exhibit a strong dependency on the transcriptional cyclin-dependent kinases, 7 and 9 (CDK7/9). Treatment of BAP1-deficient UM cell lines with SY-5609, a CDK7 inhibitor, led to growth inhibition associated with stalled cell cycle progression. Casein kinase 1 alpha (CK1α) is highly expressed in BAP1-deficient UM patient tumors and treatment of BAP1-deficient UM cell lines with A51, a CDK7/9 plus CK1α inhibitor led to both cell cycle arrest and induction of cell death. RNA-sequencing and protein array analysis associated A51 effects with down-regulation of the pro-survival protein, MCL1. Depletion of MCL1 enhanced cell death in SY-5609-treated UM cells, whereas overexpression of MCL1 rescued cell death in A51-treated UM cells. In a non-invasive in vivo liver injection model of UM tumor growth, A51 reduced tumor onset and improved overall survival. Overall, these studies show that A51 causes cell death in advanced-stage UM preclinical models, at least in part, through down-regulating MCL1.
Authors
- Inna Chervoneva (ORCID: https://orcid.org/0000-0002-9104-4505)
- Jorge Silvio Gutkind (ORCID: https://orcid.org/0000-0002-5150-4482)
- Eric Hung (ORCID: https://orcid.org/0000-0002-7943-5589)
- Michael A. Davies (ORCID: https://orcid.org/0000-0002-0977-0912)
- Irit Snir-Alkalay (ORCID: https://orcid.org/0009-0001-0055-6071)
- Vivian Y.L. Chua (ORCID: https://orcid.org/0000-0002-1873-6820)
- Corinne E. Wessner (ORCID: https://orcid.org/0000-0002-5896-3841)
- Andrew E. Aplin (ORCID: https://orcid.org/0000-0002-2734-3244)
- John Robert Eisenbrey (ORCID: https://orcid.org/0000-0001-6411-3424)
- Ji‐Bin Liu (ORCID: https://orcid.org/0000-0003-2979-9162)
- Yinon Ben‐Neriah (ORCID: https://orcid.org/0000-0003-1660-715X)
- Timothy J. Purwin (ORCID: https://orcid.org/0000-0002-7053-8039)
- Jelan I. Haj (ORCID: https://orcid.org/0009-0001-3576-8955)
- Francis J. Waltrich (ORCID: https://orcid.org/0009-0004-7579-9846)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Thomas Jefferson University (US)
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- University of California San Diego (US)
Publication Details
- Journal
- Molecular Cancer Therapeutics
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1158/1535-7163.mct-26-0850
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00